Russ 2003.

Methods	Design: open‐label RCT (Australian Rapamune‐Tacrolimus Study Group) Duration: not reported Follow up: 6 months
Participants	Setting: multicentre (7 centres) Country: Australia Adult kidney transplant recipients; 1st or 2nd DD graft or non‐HLA identical LD Number (group 1/group 2): 64 (33/31) Mean age ± SD (years): group 1 (43.9 ± 12.1); group 2 (46.9 ± 12.2) Sex (MF): group 1 (20/13); group 2 (21/10) Exclusions: sensitized patients with PRA > 50% and recipients of regrafts who had lost their first graft because of rejection within the first 6 months
Interventions	Treatment group 1 High‐SRL: adjusted for target levels 10 to 15 ng/mL rTAC: adjusted for target levels 3 to 7 ng/mL Treatment group 2 Low‐SRL: adjusted for target levels 5 to 10 ng/mL sTAC: adjusted for target levels 10 to 15 ng/mL Co‐interventions Prednisolone
Outcomes	Death (all causes) Graft loss censored for death Graft loss or death with a functioning graft Acute rejection CrCl SCr Malignancy
Notes	Comparison: variable dose of TOR‐I and CNI
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to permit judgement
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open‐label study
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Outcomes laboratory based and unlikely to be influenced by lack of blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT analysis
Selective reporting (reporting bias)	Low risk	Prespecified outcomes reported
Other bias	High risk	Funded by Wyeth